The prevailing treatment paradigm for newly diagnosed multiple myeloma (NDMM) patients who have received autologous stem cell transplantation (SCT) primarily consists of chemotherapy or Johnson & Johnson’s (J&J) Darzalex in combination with chemotherapy. The GRIFFIN study analysed 207 NDMM transplant-eligible […]
J&J’s Tecvayli shows promise in transplant-eligible NDMM patient Read More »
Leading obesity drugmaker Lilly has announced a £279m ($365.5m) investment in the UK in a major collaboration between the company and the UK government. The announcement was made during October 2024’s International Investment Summit in London, emphasising the UK’s ambition
Lilly’s £279m bet aims to boost UK life sciences sector Read More »
Pleural fluid cytology showing involvement by malignant cells of a mantle cell lymphoma, pleomorphic variant.. Image credit: Shutterstock/David A Litman Data from the Phase II ELM-2 trial was presented at the American Society of Hematology (ASH) 2024 Annual Meeting, held
ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope Read More »
The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM) – comprising the US, the five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and Australia – is forecast to grow from $582m in
RSV prophylactic market to reach $6.2bn in 8MM by 2030 Read More »
Investment for companies developing cell and gene therapies (CGTs) was discussed during the Genscript Biotech Global Forum London 2024 conference held on 20 November 2024. Following a sharp drop in CGT investment in 2022, trends suggest that CGT investment is
Cell and gene therapy companies must demonstrate strong value proposition for investment Read More »
On 26 September 2024, Cobenfy (KarXT) gained US Food and Drug Administration (FDA) approval as the first novel class of antipsychotics in decades. Developed by Karuna Therapeutics, recently acquired by Bristol Myers Squibb, Cobenfy diverges from the industry’s dopamine-dominated approach,
the muscarinic path to safer antipsychotics Read More »
As US President-Elect Donald Trump, who will return to the White House in late January 2025, appoints healthcare agency heads, industry insiders state that moods are mixed, varying from panic to excitement. Confirmation hearings early in 2025 will reveal more
Trump agency nominations show pharma industry as divided as US Read More »
In recent years, GLP-1 receptor (GLP-1R) products have gained immense popularity. Currently, four innovative GLP-1Rs are approved worldwide for obesity, all of which are injectables. This leaves a gap in the obesity market for an oral GLP-1R product. 63 drugs
oral GLP-1R therapies in obesity Read More »
In recent years, the evolution of biologic therapies for severe asthma has paralleled advancements in other chronic conditions such as rheumatoid arthritis and psoriasis, where biologics have also transformed treatment paradigms. One common trend is the increasing focus on identifying
The biologic revolution in asthma treatment Read More »
In an advancement for diabetes management, the US Food and Drug Administration (FDA) has granted clearance to Medtronic’s new InPen app, setting the stage for the launch of the company’s Smart MDI system integrated with the Simplera continuous glucose monitor
FDA approves Medtronic InPen app, launching Smart MDI system with Simplera CGM Read More »
